Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. (Q35153623)

6 August 2017

title

Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. (English)

1 reference

6 August 2017

main subject

systemic mastocytosis

1 reference

1 reference

Sabine Cerny-Reiterer

2

object named as

Sabine Cerny-Reiterer

0 references

Christine Mannhalter

6

object named as

Christine Mannhalter

1 reference

6 August 2017

Peter Valent

1

1 reference

6 August 2017

Gregor Hoermann

3

1 reference

6 August 2017

Wolfgang R Sperr

4

1 reference

6 August 2017

Leonhard Müllauer

5

1 reference

6 August 2017

Hubert Pehamberger

7

1 reference

6 August 2017

publication date

15 December 2014

1 reference

American journal of blood research

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

93-100

1 reference

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mast cell activation syndrome: Proposed diagnostic criteria.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mastocytosis and insect venom allergy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mast cell proliferative disorders: current view on variants recognized by the World Health Organization

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Diagnosis and treatment of systemic mastocytosis: state of the art.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mastocytosis: current concepts in diagnosis and treatment

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Cutaneous mastocytosis -- clinical heterogeneity.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Diagnostic criteria and classification of mastocytosis: a consensus proposal

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Clinical and histopathological aspects of cutaneous mastocytosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

c-kit mutational analysis in paraffin material

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Systemic mastocytosis and bone involvement in a cohort of 75 patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351647

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

16 November 2018

1 reference

12 December 2020

Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis

1 reference

12 December 2020

Systemic mastocytosis

1 reference

12 December 2020

1 reference

12 December 2020

Diagnostic value of immunostaining for tryptase in patients with mastocytosis

1 reference

12 December 2020

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults

1 reference

12 December 2020

Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis

1 reference

12 December 2020

Identifiers

PMC publication ID

4351647

1 reference

6 August 2017

1 reference